Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: Prospective Phase II Clinical Study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038987

Enrollment

Unknown

Registered

2020-10-12

Start date

2019-01-30

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

experimental group:PBI combined with Conbercept

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with refractory PCV (continuous injection of 6 needles or combined with PDT treatment, the effusion has not been absorbed); Patients with recurrent PCV (recurrence of effusion after continuous injection of 6 needles or combined with PDT).

Exclusion criteria

Exclusion criteria: 1. Patients with vision loss caused by other diseases; 2. Patients whose axial length is less than 20 mm or more than 26 mm; 3. Patients with type I or type II diabetes.

Design outcomes

Primary

Measure	Time frame
BCVA;CMT;	—

Secondary

Measure	Time frame
the area of BVN;the regression rates of polyps;	—

Countries

China

Contacts

Public ContactLiu Wei

Ophthalmology and Otolaryngology Hospital Affiliated to Fudan University

Bfgf2020@163.com+86 13916679479

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026